STAT+: Will Geron be acquired? The long-short view

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

I’m back from my ASCO-Chicago detour. I missed you all!

This week, let’s argue over Geron’s future and consider Candel Therapeutics to illustrate why survival claims from non-randomized studies are too often red flags. I sound like a biotech nerd. I guess I am.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Will Geron be acquired? The long-short view »